A recent study conducted by the AMA has revealed a significant relationship between the utilization of medical cannabis and notable enhancements in the quality of life experienced by individuals grappling with conditions like insomnia and chronic pain. In a comprehensive retrospective analysis, the researchers examined a sample of 3,148 individuals from Australia that had been prescribed medical cannabis to alleviate symptoms associated with various qualifying diseases.
The study found that cannabis appeared to be beneficial for all eight well-being indicators that were examined, with negative side effects that were infrequently severe.
Throughout their treatment, patients were tasked with assessing their overall well-being across eight distinct categories using a scale ranging from 0 to 100. These categories included bodily pain, general health, physical functioning, mental health, physical role restrictions, emotional role restrictions, vitality and social functioning.
The survey was administered to patients at approximately 45-day intervals, resulting in a total of 15 check-ups. The study discovered that those who used marijuana reported an average benefit range of 6.5 to 18.30 points on a scale of 100. Among the medical conditions for which cannabis has been prescribed, the ones that stood out were chronic pain, accounting for a substantial 68.6% of cases; pain resulting from cancer treatment at 6.0%; insomnia, with a prevalence of 4.8%; and anxiety disorders, accounting for 4.2% of cases.
Patients used a wide range of marijuana products with different cannabinoid compositions, dosages and intake techniques. Even so, there was little difference between the final effects. The researchers also noted a limitation in the study’s retrospective analytic technique, which resulted in a lack of control, making extrapolating the findings more difficult.
This study is only one of many recent research projects showcasing the medicinal advantages of marijuana, reflecting the growing global trend of countries revising their cannabis regulations. For instance, another AMA study revealed that patients with chronic pain who used medical marijuana for more than a month experienced a considerable drop in the amount of opioids they were prescribed.
Last year, the AMA released studies that revealed a significant correlation between the legalization of cannabis in certain states and a reduction in opioid prescriptions among specific cancer patients. Moreover, numerous other studies have consistently demonstrated a connection between the legalization of marijuana and a decline in opioid prescription rates as well as a decrease in the number of overdose fatalities.
Chronic pain comes out prominently as one of the conditions for which patients report benefiting from medical marijuana. It may come as no surprise that enterprises such as IGC Pharma Inc. (NYSE American: IGC) are seeking to develop FDA-approved formulations from cannabis to treat chronic pain and other symptoms.
NOTE TO INVESTORS: The latest news and updates relating to IGC Pharma Inc. (NYSE American: IGC) are available in the company’s newsroom at https://cnw.fm/IGC
CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.
To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CNW420.com
Do you have questions or are you interested in working with CNW420? Ask our Editor
CNW420 is part of the InvestorBrandNetwork.